ICON Public Limited (NASDAQ:ICLR) Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC lessened its position in ICON Public Limited (NASDAQ:ICLR) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 203,322 shares of the medical research company’s stock after selling 6,750 shares during the quarter. TimesSquare Capital Management LLC’s holdings in ICON Public were worth $57,554,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Liontrust Investment Partners LLP boosted its stake in ICON Public by 108.4% during the 3rd quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after purchasing an additional 46,739 shares during the last quarter. Chartwell Investment Partners LLC grew its stake in ICON Public by 16.1% during the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock valued at $1,712,000 after acquiring an additional 963 shares in the last quarter. Whittier Trust Co. raised its holdings in ICON Public by 6.2% in the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock valued at $765,000 after acquiring an additional 158 shares during the last quarter. Cullen Investment Group LTD. acquired a new position in shares of ICON Public during the 4th quarter worth approximately $1,620,000. Finally, Prime Capital Investment Advisors LLC purchased a new stake in shares of ICON Public in the fourth quarter valued at approximately $416,000. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Trading Up 1.1 %

ICLR traded up $3.29 during mid-day trading on Thursday, hitting $315.04. 396,034 shares of the stock were exchanged, compared to its average volume of 561,465. The company has a market cap of $25.99 billion, a PE ratio of 37.93, a PEG ratio of 1.39 and a beta of 1.18. ICON Public Limited has a 1-year low of $188.45 and a 1-year high of $344.77. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average is $319.01 and its two-hundred day moving average is $286.95.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.13. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.08 billion. Equities analysts forecast that ICON Public Limited will post 14.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on ICLR. Robert W. Baird raised their target price on ICON Public from $362.00 to $363.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Barclays boosted their target price on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Mizuho restated a “buy” rating and set a $346.00 price target on shares of ICON Public in a report on Thursday, April 4th. TD Cowen increased their price objective on ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Finally, Truist Financial lifted their target price on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, ICON Public presently has an average rating of “Moderate Buy” and an average price target of $339.44.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.